Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study.

Autor: Vandtved JH; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Øvlisen AK; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Baech J; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Weinrich UM; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.; Department of Respiratory Diseases, Aalborg University Hospital, Aalborg, Denmark., Severinsen MT; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Maksten EF; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Jakobsen LH; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Glimelius I; Department of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden., Kamper P; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Hutchings M; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Specht L; Department of Oncology, Rigshospitalet, Copenhagen, Denmark., Dahl-Sørensen R; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Christensen JH; Department of Hematology, Odense University Hospital, Odense, Denmark., El-Galaly TC; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.; Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.; Department of Hematology, Odense University Hospital, Odense, Denmark.; Department of Medicine Solna, Division of Clinical Epidemiology, Karolinska Institute, Stockholm, Sweden.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2024 Aug; Vol. 205 (2), pp. 542-551. Date of Electronic Publication: 2024 Apr 29.
DOI: 10.1111/bjh.19475
Abstrakt: Late toxicities can impact survivorship in patients with classical Hodgkin lymphoma (cHL) with pulmonary toxicity after bleomycin-containing chemotherapy being a concern. The incidence of pulmonary diseases was examined in this Danish population-based study. A total of 1474 adult patients with cHL treated with ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or BEACOPP (bleomycin, vincristine, etoposide, doxorubicin, cyclophosphamide, procarbazine and prednisone) between 2000 and 2018 were included along with 7370 age- and sex-matched comparators from the background population. Median follow-up was 8.6 years for the patients. Patients with cHL had increased risk of incident pulmonary diseases (HR 2.91 [95% CI 2.30-3.68]), with a 10-year cumulative risk of 7.4% versus 2.9% for comparators. Excess risks were observed for interstitial lung diseases (HR 15.84 [95% CI 9.35-26.84]) and chronic obstructive pulmonary disease (HR 1.99 [95% CI 1.43-2.76]), with a 10-year cumulative risk of 4.1% and 3.5% respectively for patients. No excess risk was observed for asthma (HR 0.82 [95% CI 0.43-1.56]). Risk factors for interstitial lung diseases were age ≥60 years, the presence of B-symptoms and low albumin. These findings document a significant burden of pulmonary diseases among patients with cHL and emphasize the importance of diagnostic work-up of pulmonary symptoms.
(© 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: